Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo approach aims to tame transplant complications in bone marrow cancer

NCT ID NCT04370301

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with myelofibrosis, a type of bone marrow cancer. It tests whether giving a JAK inhibitor drug before, during, and after a half-matched stem cell transplant can lower the risk of graft-versus-host disease (a common complication where donor cells attack the body) without raising the chance of graft failure. About 20 adults aged 18 to 70 with intermediate or high-risk disease will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact